SGLT-2 inhibitor cuts need for diuretics in HFpEF, study shows 

But a US cardiologist says changing diuretic therapy would be 'unnecessary' in most patients.
Rachel Fieldhouse

Empagliflozin may reduce long-term use of diuretics in older adults with heart failure with preserved ejection fraction, according to international researchers. 

Their study results suggested patients treated with the SGLT-2 inhibitor were 43% more likely to permanently discontinue diuretic therapy compared with placebo.